Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

Celcuity’s shares dropped ~8% in premarket after the commercial launch of its newly approved breast cancer drug was delayed, with treatment-tolerability concerns outweighing the significance of its first U.S. approval.

Analysis

Celcuity’s shares dropped ~8% in premarket after the commercial launch of its newly approved breast cancer drug was delayed, with treatment-tolerability concerns outweighing the significance of its first U.S. approval.